Grimwade, David <br/><br/>
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Aug 2009 
 - 3650-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2008.20.1533  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Arsenic Trioxide<br/>Arsenicals--administration & dosage<br/>Blood Chemical Analysis<br/>Bone Marrow--pathology<br/>Cohort Studies<br/>Confidence Intervals<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Leukemia, Promyelocytic, Acute--drug therapy<br/>Male<br/>Middle Aged<br/>Monitoring, Physiologic--methods<br/>Multivariate Analysis<br/>Neoplasm Recurrence, Local--diagnosis<br/>Neoplasm, Residual--diagnosis<br/>Oncogene Proteins, Fusion--genetics<br/>Oxides--administration & dosage<br/>Predictive Value of Tests<br/>Probability<br/>Prognosis<br/>Proportional Hazards Models<br/>Prospective Studies<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Severity of Illness Index<br/>Survival Analysis<br/>Treatment Outcome<br/>Tretinoin--administration & dosage